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Background: Cognitive impairment is a clinically im-
portant feature of schizophrenia. Polygenic risk score 
(PRS) methods have demonstrated genetic overlap be-
tween schizophrenia, bipolar disorder (BD), major de-
pressive disorder (MDD), educational attainment (EA), 
and IQ, but very few studies have examined associations 
between these PRS and cognitive phenotypes within 
schizophrenia cases. Methods: We combined genetic 
and cognitive data in 3034 schizophrenia cases from 11 
samples using the general intelligence factor g as the pri-
mary measure of cognition. We used linear regression to 
examine the association between cognition and PRS for 
EA, IQ, schizophrenia, BD, and MDD. The results were 
then meta-analyzed across all samples. A  genome-wide 
association studies (GWAS) of cognition was conducted 
in schizophrenia cases. Results: PRS for both population 
IQ (P = 4.39 × 10–28) and EA (P = 1.27 × 10–26) were 
positively correlated with cognition in those with schiz-
ophrenia. In contrast, there was no association between 
cognition in schizophrenia cases and PRS for schiz-
ophrenia (P =  .39), BD (P =  .51), or MDD (P =  .49). 
No individual variant approached genome-wide signif-
icance in the GWAS. Conclusions: Cognition in schiz-
ophrenia cases is more strongly associated with PRS 
that index cognitive traits in the general population than 
PRS for neuropsychiatric disorders. This suggests the 
mechanisms of cognitive variation within schizophrenia 
are at least partly independent from those that predispose 
to schizophrenia diagnosis itself. Our findings indicate 
that this cognitive variation arises at least in part due 
to genetic factors shared with cognitive performance in 
populations and is not solely due to illness or treatment-
related factors, although our findings are consistent with 
important contributions from these factors.
Key words:  psychiatry/genomics/intelligence/bioinformatics
Introduction
Schizophrenia is an often debilitating, highly heritable 
mental disorder affecting around 1% of the population.1 
Individuals with schizophrenia show marked cognitive 
deficits, on average, compared with healthy controls.2 
Cognitive impairments are strongly associated with 
functional outcomes in schizophrenia, more so than pos-
itive symptoms.3 Existing treatments focus on reducing 
positive symptoms principally through the use of  anti-
psychotic medications, but neither these medications nor 
other treatments have major beneficial effects on cog-
nition. Indeed, it has been argued that antipsychotics, 
particularly at high doses, may exacerbate cognitive im-
pairment.4 Interventions, such as cognitive remediation 
therapy, have been shown to improve cognitive deficits to 
a limited extent but are not routinely available for most 
patients with schizophrenia.5
The underlying causes of cognitive impairment in 
schizophrenia have been contested because first described 
by Kraepelin6 but include factors secondary to illness-
related behaviors (eg, substance abuse and poor nutri-
tion) and drugs used in treating the disorder, eg, high-dose 
antipsychotics,7 anticholinergics,8 and benzodiazepines.9 
Nonetheless the demonstration in longitudinal 
population-based studies that cognitive impairment 
exists before schizophrenia onset10 suggests a contribu-
tion from factors that are correlated with increased lia-
bility to the disorder, including those that are etiological. 
Furthermore, evidence that cognitive performance is im-
paired in the relatives of those with schizophrenia, and is 
heritable in these families,11 indicates a genetic contribu-
tion to cognitive impairment in schizophrenia, consistent 
with the neurodevelopmental hypothesis of the disorder.
Genome-wide association studies (GWAS) have 
proven to be an effective means of identifying risk alleles 
for schizophrenia.12,13 They have also identified common 
alleles that influence population variation in meas-
ures of cognitive ability, including IQ, as well as other 
proxy measures such as educational attainment (EA). 
Furthermore, GWAS have provided evidence for shared 
genetic contributions to many of these traits (schizo-
phrenia, bipolar disorder [BD], major depressive disorder 
[MDD], IQ, and EA).14–20 Common variant GWAS have 
previously been performed on cognition in schizophrenia 
cases at smaller sample sizes.21,22
The aggregated common variant genetic liability for 
disorders and traits can be estimated in individuals by a 
metric known as the polygenic risk score (PRS). The PRS 
for schizophrenia has been shown to be weakly associ-
ated with IQ and cognition in population samples23–26 and 
appears to be associated with severity of negative, but not 
positive symptoms in those with schizophrenia.27 IQ PRS 
has been shown to be significantly associated with schizo-
phrenia diagnosis in a case/control sample.23
To date, few studies have examined the influence of 
PRS on cognition in those with schizophrenia, and those 
that have been performed have used a restricted range 
of PRSs, generally in small samples, and have found no 
convincing evidence for an association between schizo-
phrenia PRS and cognition.28–30 Aiming to obtain insights 
into the origins of cognitive impairment in those with 
schizophrenia, we report analyses of what we believe is 
the largest schizophrenia sample to date for which both 
cognitive and genetic data are available. We derived g, 
the “general intelligence factor,” as a measure of general 
cognitive ability,31 because it has been used successfully 
in population-based genetic studies,15 it captures sub-
stantial variance in cognitive ability, particularly in schiz-
ophrenia,32 and can be derived from a diverse array of 
cognitive tests across different studies.33,34
We performed a GWAS of  g within schizophrenia 
cases and systematically examined the relationship 
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between g and PRSs for psychiatric disorders and cog-
nitive traits in multiple schizophrenia case samples, 
using meta-analysis to combine the results. We had 2 
primary hypotheses. First, under the hypothesis that 
variation in cognitive impairment in schizophrenia is 
essentially a consequence of  liability to the disorder, 
with greater impairment indicating greater liability, we 
predicted that the measure of  liability to schizophrenia 
(schizophrenia PRS) would be negatively associated 
with cognitive performance in those with the disorder 
(Hypothesis 1). Alternatively, under the hypothesis that 
variation in cognitive performance in schizophrenia is 
driven by similar factors that influence cognition in the 
general population, albeit that variance occurs around 
a mean point that is lower as a consequence of  the dis-
order, we predicted that cognition-related PRS (for IQ 
and EA) would be associated with cognition in those 
with schizophrenia (Hypothesis 2). We also investigated 
whether polygenic liability to BD and MDD were asso-
ciated with cognition, testing these as negative controls, 
because both are adult disorders that genetically overlap 
with schizophrenia but do not show genetic correlation 
with IQ.19
Methods
We amalgamated genetic and cognitive data from those 
with schizophrenia and schizoaffective disorder from 
available datasets that were part of  the Schizophrenia 
Working Group of  the Psychiatric Genomics 
Consortium (PGC), as well as additional samples from 
the European Union Gene-Environment Interaction 
consortium (EUGEI) and from Ireland and Cardiff  
that have not yet been included in the published work 
of  the PGC.
PGC Samples
Of the 11 datasets in this study, 8 were part of the 
2014 PGC schizophrenia study (table 1).13 Genetic data 
accessed from PGC servers with permission of the indi-
vidual study principal investigators.
PGC Genotype Data
The PGC datasets included 2071 genotyped individuals 
of European ancestry, with research-verified diagnoses 
of schizophrenia or schizoaffective disorder for whom 
we also had sufficient cognitive data to calculate g, the 
general cognition factor. We used the quality control 
parameters reported by the PGC consortium,13 excluding 
individuals of non-European ancestry based on PCA. 
The datasets we analyzed had been imputed using the 
1000 Genomes phase 3 reference panel with the programs 
SHAPEIT for haplotype phasing and IMPUTE2 for im-
putation. Full details of sample collection, genotyping, 
quality control, and imputation are available in the asso-
ciated article.13 After imputation, variants with an INFO 
score >0.1, minor allele frequency  (MAF) >0.5% and 
missingness <2% were retained for further analysis.
EUGEI and Additional Irish Samples
A total of 156 samples with schizophrenia and 
schizoaffective disorder collected and genotyped as 
part of Work Package 2 of the EUGEI study were in-
cluded in the analysis (the European network of national 
schizophrenia networks studying gene-environment 
interactions, see http://www.eu-gei.eu/).35 These samples 
were recruited as first episode psychosis cases with a 
schizophrenia or schizoaffective disorder diagnosis based 
on Operational Criteria ratings, following a research 
Table 1. Sample Size and Details of Datasets Included in Study
Dataset name
In PGC2 SZ 
study? Country/countries of origin
Number 
of study 
participants
Gender 
(% female)
Median 
age
Age 
range
Bonn/Mannheim Yes Germany 436 42 36 17–70
PAGES Yes Germany 148 37 39 19–70
CATIE Yes United States 350 23 43 18–65
Hubin Yes Sweden 77 30 45 25–70
TOP Yes Norway 286 43 29 17–62
GROUP sample 1 Yes The Netherlands 309 23 25 16–52
GROUP sample 2 Yes The Netherlands 119 24 25 15–45
Ireland (PGC samples) Yes Ireland 346 28 42 17–69
Ireland (additional samples) No Ireland 159 35 43 19–67
EU-GEI Work Package 2 No France, Italy, Spain, the Netherlands, United 
Kingdom
156 28 30 17–59
Cardiff  cognition No United Kingdom 648 38 43 17–74
Note: PGC, psychiatric genomics consortium; PAGES, phenomics and genomics sample; CATIE, clinical antipsychotic trials for inter-
vention effectiveness; TOP, Tematisk Omrade Psykoser, GROUP, genetic risk and outcome of psychosis; EU-GEI, European Union 
Gene-Environment Interaction. Number of study participants refers to those with genomic, phenotypic and covariate data.
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interview and case note review.35 An additional 159 cases 
collected from centers across Ireland were included in the 
analysis; all had a Diagnostic and Statistical Manual of 
Mental Disorders (Fourth Edition) (DSM-IV) diagnosis 
of schizophrenia/schizoaffective disorder. For details of 
genotyping, quality control, and imputation, see supple-
mentary information.
CardiffCOGS Samples
We included 648 samples from the CardiffCOGS study 
with DSM-IV schizophrenia and schizoaffective disorder 
diagnoses, based on a SCAN interview36 and clinical note 
review ratings.37 For details of genotyping, quality con-
trol, and imputation, see supplementary information.
Neuropsychological Assessment
Participants in all studies underwent formal neuropsy-
chological testing, administered by trained researchers. 
Protocols and results from each sample have been in-
dependently published38–44 and we provide full details 
of testing procedures and batteries in supplementary 
information.
Calculation of g
The cognitive tests available differed for each study sample 
(supplementary table 1). For a dataset to be included, we 
required tests from a minimum of 2 cognitive domains, 
having assigned cognitive tests to domains based on the 
approach taken by MATRICS.45,46 We then calculated g 
independently for each dataset using at most 3 tests from 
a particular cognitive domain. Subjects were excluded if  
they did not have valid scores for at least 2 cognitive tests. 
Outlier test scores were also excluded (supplementary 
information).
g was calculated from the cognitive test scores using 
multidimensional scaling (MDS), as implemented in the 
R “stats” package. Unlike principal component anal-
ysis (PCA), MDS can retain subjects with missing data 
while being mathematically analogous to PCA when 
data are complete. g was calculated as the first dimension 
produced by MDS analysis.
For 5 datasets, values of g were calculated using both 
MDS and PCA in samples with no missing data, and the 
results examined for correlation (see supplementary data 
and supplementary table 2 for more details). For PCA, 
the first principal component was taken to represent 
g. PCA- and MDS-derived estimates of g were highly 
correlated (|r| > 0.95 in all datasets), endorsing our selec-
tion of MDS to derive g. A version of the primary anal-
ysis using values of g derived from PCA (thus excluding 
missing data) was also performed.
For the EUGEI sample, Wechsler Adult Intelligence 
Scale  (WAIS) IQ estimates were available. Given their 
high correlation with g, and also because WAIS IQ had 
been standardized across the multiple countries present 
in the EUGEI dataset, we used these scaled IQ scores 
for the EUGEI samples. This methodology follows the 
approach taken in equivalent research in nonclinical 
populations.23
Genome-Wide Association Analysis of g and 
Meta-analysis
Mixed linear model association was performed genome-
wide in each dataset using the program Genome-wide 
Complex Trait Analysis,47,48 which calculates a genetic 
relationship matrix (GRM) for all samples that are then 
used to correct for sample relatedness and population 
stratification. To prevent overcorrection due to the in-
clusion of truly associated variants in the GRM, a leave-
one-chromosome-out model was used where the GRM 
used for association testing for any variant on a given 
chromosome was derived after excluding all variants 
on that chromosome. The association results for the 11 
datasets were combined using a standard error weighted, 
fixed effects meta-analysis in METAL.49
PRS Construction
PRSs were constructed from GWAS of 5 disorders or 
traits as training sets (supplementary table  3); schizo-
phrenia, major depression (MDD), BD, EA (measured 
in “years in education”), and IQ.13,18,19,50,51 The schiz-
ophrenia training set was based on the PGC2 meta-
analysis but excluded the cognitively informative samples 
used in this study for analysis of PRS and g. Clumping 
was performed in imputed best-guess genotypes for 
each dataset using PLINK (maximum r2 = 0.2, window 
size = 500 kb, minimum MAF= 10%, minimum INFO 
score = 0.7), and variants within regions of long-range 
LD (including the MHC) excluded.52 PRS were then 
constructed from best-guess genotypes using PLINK at 
10 P value thresholds (PT = 1, .5, .3, .2, .1, .05, .01, 1 × 
10–4, 1 × 10–6, 5 × 10–8). We used PT = .05 for our primary 
analyses, except for MDD, where we used PT = 0.5 (sup-
plementary information).
Regression of g on PRS and Meta-analysis
The relationships between g and PRS were analyzed in 
each schizophrenia dataset using linear regression in 
R, with age, sex, and population principal components 
as covariates (supplementary table  4). PRS and g were 
normalized to have a mean of 0 and a standard deviation 
of 1, and so resulting effect size estimates give the number 
of standard deviations change in g for 1 standard devi-
ation change in PRS. Results for each PRS were meta-
analyzed across all datasets with a fixed-effects model 
using the metagen function in the “meta” package in R. I2 
values and random effects meta-analysis P values were 
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also calculated to examine the extent of heterogeneity in 
our sample.
To ensure that the results were not biased by samples 
with a small number of available cognitive tests, or by 
the use of WAIS IQ in place of g in the EUGEI sample, 
we also performed sensitivity analyses, which excluded 
the EUGEI sample, and also individuals from 2 of the 
samples (Mannheim/Bonn and Ireland) for whom we had 
data for only 2 cognitive tests. Inclusion in the regression 
model of an age by sex interaction term and a nonlinear 
effect of the age covariate produced consistent results.
Power calculations for the PRS analyses are presented 
in supplementary information. For all training sets except 
BD, our power to detect true effects was estimated to be 
over 99% (supplementary table 3).
Independent Population Samples
To examine whether the results for PRS predicting cogni-
tion in schizophrenia cases were comparable with results 
in a population-based sample, we tested the association 
between the IQ PRS (Savage et al19) and IQ in an inde-
pendent dataset, the second wave of the Biobank sample 
(n = 91 468, PT = .05, IQ measure: fluid intelligence score, 
UK Biobank field ID: 20016). We also tested the asso-
ciation between SZ PRS (Pardinas et al12) and IQ in the 
complete Biobank sample (n = 133 437, PT = .05; supple-
mentary information).
The analytic methods followed those of the main 
schizophrenia analysis and used population principal 
components, age at cognitive assessment, and sex as 
covariates (supplementary table 4). UK Biobank analyses 
were conducted under project number 13310.
Results
Consistent with other similarly sized GWAS of com-
plex traits, no variants reached a genome-wide level 
of significance for association with g. (Supplementary 
figure 1—Manhattan plot; supplementary figure 2—Q-Q 
plot (λ = 1.027); supplementary table 5—top hits; results 
available at https://walters.psycm.cf.ac.uk/).
With respect to our primary hypotheses, we found no 
evidence to support the predictions of hypothesis 1, in that 
we observed no association between the schizophrenia 
PRS and g in schizophrenia cases (table 2; supplementary 
figure 3). Thus, in our sample, common variant liability 
to schizophrenia was not associated with cognitive per-
formance as measured by g. In contrast, a significant pos-
itive relationship was found between g and PRS derived 
from both IQ (P = 4.39 × 10–28, effect size = 0.199) and 
EA (P = 1.27 × 10–26, effect size = 0.188), supporting hy-
pothesis 2 (table 2; figure 1; and supplementary figure 4). 
These effect sizes were larger in magnitude than those 
observed for SZ, BD, and MDD PRS, but somewhat 
smaller than those observed for the association of IQ PRS 
and fluid intelligence in non-psychotic individuals from 
the independent UK Biobank samples (P < 2.2 × 10–16, 
effect size = 0.327). Similar results were obtained across 
differing P value thresholds (supplementary table 6).
Sensitivity analysis following exclusion of the EUGEI 
samples (WAIS IQ was used instead of g) and samples 
with data on only 2 cognitive tests were consistent with 
the primary analyses (supplementary table  7). Similar 
results were observed when random effects meta-analysis 
was used to minimize the effect of intersample heteroge-
neity (supplementary table  6). The magnitude and pat-
tern of results remained unchanged when the calculation 
of g used a traditional PCA approach (thus excluding 
participants with any missing cognitive test data). SZ 
PRS significantly predicted fluid intelligence in non-
psychotic individuals in the Biobank sample (P < 2.2 × 
10–16, effect size = –0.137), though again with a smaller 
effect size than when using IQ PRS.
Secondary negative control analyses revealed no signif-
icant relationship between g and PRS for BD or MDD 
(table 2; supplementary table 6).
Discussion
Here, we report a genome-wide investigation of what is, 
to date, the largest schizophrenia sample with both cog-
nitive and genetic data. Given that much larger samples 
are generally required to yield robust association signals 
for complex phenotypes and that this is true for general 
cognition in population samples,23 our aim was not to 
implicate loci associated with cognition within schizo-
phrenia. Rather, our primary aim was to investigate the 
relationships between cognitive performance in people 
with schizophrenia and common variant genetic liability 
to both schizophrenia and to cognitive ability in the 
general population.
Specifically, we tested 2 primary hypotheses. First, under 
the hypothesis that variation in cognitive impairment in 
Table 2. Meta-analysis of Regression of g on PRS
Training set P value threshold Effect size Standard error P value
Schizophrenia .05 –0.017 0.019 .386
Bipolar disorder .05 –0.012 0.018 .509
Major depression .5 –0.013 0.018 .488
IQ .05 0.199 0.018 4.39E–28
Educational attainment .05 0.188 0.018 1.27E–26
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schizophrenia is a function of the degree of liability to 
the disorder, with greater impairment indicating greater 
liability, we predicted that the measure of liability to 
schizophrenia would be negatively associated with cog-
nitive performance in those with the disorder. This hy-
pothesis was not supported, as there was no significant 
relationship between schizophrenia PRS and g, although 
we cannot exclude the possibility that a significant rela-
tionship will emerge with further increases in sample size. 
The second hypothesis was that genetic variation in cog-
nitive performance in schizophrenia is essentially driven 
by factors that influence cognition in the general popula-
tion, leading to the prediction that cognition related PRS 
based on the general population would be associated with 
cognition in those with schizophrenia. In contrast to hy-
pothesis 1, we found strong evidence to support the pre-
diction from hypothesis 2, PRS for IQ and for EA being 
strongly associated with g in those with schizophrenia. As 
predicted, we found no evidence of association between 
liability to MDD or BPD and g.
Overall, our results suggest that alleles associated with 
IQ and EA in the general population make a more im-
portant contribution to variance in cognition in those 
with schizophrenia than the alleles that confer liability to 
schizophrenia per se. This interpretation, however, only 
holds if  we assume the schizophrenia PRS captures a sim-
ilar, or greater, proportion of the liability to that disorder 
than IQ and EA do for their respective traits. Previous 
studies have shown this assumption to be valid, indeed 
the IQ PRS explains a smaller proportion of variance in 
IQ than the proportion of variance of schizophrenia case 
status explained by the schizophrenia PRS (liability scale 
R2  =  0.052 for IQ, 0.07 for schizophrenia, 0.106–0.127 
for EA).13 Thus, the schizophrenia PRS is actually better 
powered to test the impact of schizophrenia liability than 
the IQ PRS, allowing us to conclude that differential 
power is unlikely to explain our finding. Furthermore, the 
fact that the IQ and EA PRS predict cognition in cases 
indicates that the failure to detect a relationship between 
cognition and schizophrenia liability is not due to cogni-
tion measurement errors. Together, these considerations 
support the hypothesis that variance in cognition in 
schizophrenia and in the general population has common 
genetic causes.
We went on to examine whether the variance in cog-
nition explained by the PRS for IQ was quantitatively as 
well as qualitatively similar in people with schizophrenia 
compared with those drawn from the wider population 
(figure 1). This showed that the IQ PRS explained less of 
the variance in cognition in schizophrenia than in an in-
dependent population sample (UK Biobank—UKBB53). 
We consider this to be only an approximate compar-
ison of variance; an accurate comparison would require 
representative sampling at scale (population and case) 
and identical tests, neither condition being met in our 
schizophrenia sample. The IQ PRS was derived in large 
part from the UKBB (wave 1), which also provided our 
(nonoverlapping) independent test dataset for the popu-
lation IQ analysis (wave 2 of UKBB). Thus, the obser-
vation that the variance explained in schizophrenia cases 
is modestly lower than in the UKBB population sample 
could be due, at least in part, to the more uniform cog-
nitive assessment and similarity of sample character-
istics (more restricted age range and demographics) in 
UKBB, which would serve to reduce unsystematic var-
iation and increase power relative to the analysis in SZ 
cases. However, our result is also consistent with impor-
tant contributions to cognitive impairment in those with 
schizophrenia from factors that are illness-related; pos-
sible examples include delays in treatment, symptom se-
verity and chronicity, pre- and post-natal complications, 
social isolation, as well as drug exposures (therapeutic or 
abused).7–9,54
The fact that schizophrenia polygenic alleles en masse 
are not associated with variation in cognition in those 
with schizophrenia does not contradict previous findings 
that individual schizophrenia risk alleles or genes in-
fluence cognition or EA,17 indeed we and others have 
reported consistent negative associations between schiz-
ophrenia PRS and performance on specific cognitive 
domains and EA in population samples,23,25 and show 
here that schizophrenia PRS shows a negative associa-
tion with cognition in the UKBB. The fact that we did 
Fig. 1. Forest plot showing effect sizes and confidence intervals 
for regression of g on IQ polygenic risk score (age, sex, and 
population principal component covariates also included in 
model) in schizophrenia case samples and an independent IQ 
sample. Effect sizes based on standardized values of g/IQ and 
polygenic risk score (PRS; ie, number of standard deviations 
change in g/IQ that occurs with 1 standard deviation change in 
PRS). Lower panel shows regression of IQ on IQ polygenic risk 
score in an independent population dataset, the second wave of 
the UK Biobank (n = 91 468).
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not detect a similar negative association in cases may be 
partly attributable to the schizophrenia samples effec-
tively having been selected for high schizophrenia PRS 
and thus attenuating our power to examine whether var-
iation in schizophrenia PRS is associated with cognition. 
To examine this as a potential explanation of our results, 
we plotted the distributions and calculated metrics of 
normality for both the schizophrenia and IQ PRS (sup-
plementary figures 5 and 6). These distributions and met-
rics are very similar between the schizophrenia and IQ 
PRS and are not suggestive of a restricted distribution, 
hence, although a theoretical concern, the distribution of 
schizophrenia PRS seems unlikely to explain our findings.
Our findings thus argue against universal pleiotropy 
for schizophrenia alleles and cognition. Nonetheless, 
our results do not suggest that schizophrenia risk alleles 
have no role in cognition that seems unlikely given the 
highly significant relationship between schizophrenia 
PRS and case/control status and the similarly robust cog-
nitive impairments in cases relative to controls. Robust 
associations between SZ PRS and cognition in the 
general population, as we confirm, are further evidence 
against this. Rather, our findings suggest that the effect 
of schizophrenia risk alleles on cognition is well captured 
by the schizophrenia diagnosis. In other words, the schiz-
ophrenia PRS may contribute more to case-control cog-
nitive differences than it does to the variance of cognition 
within cases, which is the subject of this study. The im-
pact of schizophrenia alleles on cognitive functioning 
within cases must be small or absent and is certainly con-
siderably less than the effect of alleles that contribute to 
IQ and EA PRS.
We acknowledge some limitations of our study design. 
Cross-sample cognitive analyses typically are hampered 
by differing test battery selection and administration. In 
this study, we sought to mitigate this by using g as a cog-
nitive metric, which allows the incorporation of samples 
that use a diverse set of cognitive tests and has the ben-
efit of ease of interpretation and comparison within and 
between studies. Despite this, heterogeneous effects re-
lated to test administration and sample ascertainment 
present challenges to combining cognitive data cross-site, 
although our findings suggest validity to our methods 
given the concordant results with equivalent population 
IQ studies. By conducting within sample PRS cognition 
analysis followed by meta-analysis, we also avoided the 
need to directly combine cognitive test results across 
samples. It is further reassuring that the subsets of our 
data do not show large amounts of variation in terms of 
the relationship between PRS and g (see forest plots in 
supplemental figures  3–4), and that cognitive PRS was 
in fact associated with g in our sample. Our study does 
not address the contribution of rare high-penetrance 
variants; however, although rare copy number variants 
and loss of function mutations clearly influence cogni-
tion and disorder liability, those that are currently known 
to do so are cumulatively so rare (2%–3% of cases) that 
they cannot contribute substantially to cognitive variance 
in the population of cases.55,56 Finally, we note our sample 
lacks matched healthy controls for whom similar cogni-
tive data have been obtained, and therefore we cannot di-
rectly evaluate to what extent the cognitive PRS explains 
the average cognitive differences between those with and 
without the disorder. Despite the limitations of polygenic 
analysis with current sample sizes in explaining vari-
ance explained, it is unlikely that the major differences 
in cognition (1 to 2 standard deviations) seen between 
schizophrenia cases and healthy controls are explained 
by common genetic factors alone and that rare genetic 
variants and nongenetic exposures are likely to have im-
portant roles in etiology.
In conclusion, the existence of a genetic contribution 
to cognition in schizophrenia that is not secondary to the 
disorder per se has previously been inferred from findings 
that at least some of the cognitive impairment in people 
with schizophrenia predates the onset of the condition,10 
and by the fact that cognitive impairments are observed, 
albeit in a milder form, in relatives of those with schiz-
ophrenia.57 We now extend these findings, showing for 
the first time that polygenic contribution to cognition 
overlaps in population and schizophrenia samples. We 
further show that in those with schizophrenia, variance 
in cognition is substantially independent of common var-
iant liability to the disorder. This is important because 
it suggests the underlying biology of variation in cogni-
tion in schizophrenia will at least in part be elucidated 
through gaining insights into the genetic basis of cogni-
tion in population samples, and that such characteriza-
tion may provide insights to inform the development of 
therapeutics for cognitive deficits in schizophrenia.
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